IQIRVO: payments to doctors
Payments that named IQIRVO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.2M
- Providers
- 8,152
- Transactions
- 25,118
- Average per transaction
- $168
The per-transaction average — $168 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,152 providers the average total is $519, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $4,139,307 | 97.9% |
| Ipsen Innovation | $83,372 | 2.0% |
| Albireo Pharma, Inc. | $3,812 | 0.1% |
| Ipsen Pharma SAS | $1,762 | 0.0% |